Based on the results of the REGAIN and PREVENT studies, eculizumab is now FDA-approved for refractory AChR IgG-positive myasthenia gravis and AQP4-IgG-positive relapsing NMOSD [146, 147]. Here, AQP4 is linked to myasthenia gravis.